We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$17.7M
Cap. Flow
+$87.9M
Cap. Flow %
7.94%
Top 10 Hldgs %
56.11%
Holding
90
New
21
Increased
23
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
PFE icon
Pfizer
PFE
+$15.7M
3
UTHR icon
United Therapeutics
UTHR
+$15.6M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.3M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$22.8M
2
NVO
Novo Nordisk
NVO
+$16.5M
3
HRTX icon
Heron Therapeutics
HRTX
+$9.45M
4
INCY icon
Incyte
INCY
+$5.91M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 87.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$107M 9.67%
1,109,874
+10,050
+0.9% +$1.12M
NTRA icon
2
Natera
NTRA
$37.5B
$102M 9.2%
3,100,560
– –
AMRN
3
Amarin Corp
AMRN
$284M
$79M 7.14%
260,415
– –
NXTC icon
4
NextCure
NXTC
$17.3M
$77.8M 7.03%
210,155
– –
YMAB
5
DELISTED
Y-mAbs Therapeutics
YMAB
$54.8M 4.96%
2,104,278
– –
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$46.7M 4.22%
481,270
– –
PRNB
7
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$40M 3.62%
1,417,258
-620,950
-30% -$22.8M
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
$39.6M 3.58%
4,749,623
– –
CHRS icon
9
Coherus Oncology
CHRS
$217M
$39.2M 3.54%
1,933,221
-160,000
-8% -$3.2M
MRUS
10
DELISTED
Merus
MRUS
$34.9M 3.16%
1,961,039
– –
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.2M 2.55%
1,729,352
– –
XLB icon
12
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.51B
$27M 2.44%
+600,000
New +$17.3M
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
$26.2M 2.37%
933,640
– –
BMY icon
14
Bristol-Myers Squibb
BMY
$127B
$24.3M 2.19%
478,349
+304,500
+175% +$14.3M
AGN
15
DELISTED
Allergan plc
AGN
$22.6M 2.05%
134,433
+50,000
+59% +$8.15M
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$121B
$20.6M 1.86%
121,690
+71,389
+142% +$12.6M
AMGN icon
17
Amgen
AMGN
$203B
$17.9M 1.61%
+92,300
New +$17.7M
NBIX icon
18
Neurocrine Biosciences
NBIX
$17.7B
$17.3M 1.56%
191,679
+35,819
+23% +$3.35M
NCNA
19
NuCana
NCNA
$5.37M
$16.4M 1.48%
453
– –
XLRN
20
DELISTED
Acceleron Pharma
XLRN
$16.1M 1.46%
408,262
+167,219
+69% +$7.25M
UTHR icon
21
United Therapeutics
UTHR
$26.3B
$15.5M 1.4%
+194,014
New +$15.6M
PFE icon
22
Pfizer
PFE
$140B
$14.8M 1.33%
+432,780
New +$15.7M
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.9M 1.08%
148,669
+33,133
+29% +$2.81M
RETA
24
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.9M 1.08%
+148,600
New +$12.6M
ITRM
25
DELISTED
Iterum Therapeutics
ITRM
$9.96M 0.9%
115,101
– –
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Sofinnova Investments held 90 positions worth $1.11B, up 1.6% from $1.09B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sofinnova Investments deployed $87.9M of net new capital in Q3 2019, opening 21 new positions and adding to 23 existing holdings. Its largest new stake was Amgen: 92,300 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $22.8M trimmed.

  • Sofinnova Investments's largest Q3 2019 buy was Amgen: 92,300 shares worth $17.9M.
  • Sofinnova Investments added most to Bristol-Myers Squibb in Q3 2019, an estimated $14.3M increase.
  • Sofinnova Investments's biggest Q3 2019 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $22.8M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2019, selling an estimated $16.5M.
  • Sofinnova Investments's ten largest holdings make up 56% of its $1.11B portfolio in Q3 2019.
  • Sofinnova Investments opened 21 new positions and closed 19 in Q3 2019.
  • Sofinnova Investments's portfolio value rose 1.6% quarter-over-quarter to $1.11B.

Based on Sofinnova Investments's 13F filing for Q3 2019, filed 14 Nov 2019.